TY - JOUR
T1 - Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma
AU - Calzada, Oscar
AU - Switchenko, Jeffrey M.
AU - Maly, Joseph J.
AU - Blum, Kristie A.
AU - Grover, Natalie
AU - Mathews, Stephanie
AU - Park, Steven I.
AU - Gordon, Max
AU - Danilov, Alexey
AU - Epperla, Narendranath
AU - Fenske, Timothy S.
AU - Hamadani, Mehdi
AU - Flowers, Christopher R.
AU - Cohen, Jonathon B.
N1 - Funding Information:
This work received grant funding from the Lymphoma Research Foundation, the American Society of Hematology and National Cancer Institute. Research reported in this publication was supported in part by the Biostatistics and Bioinformatics Shared Resource of Winship Cancer Institute of Emory University and NIH/NCI under award number 3P30CA138292-06S1. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2018/12/2
Y1 - 2018/12/2
N2 - Prospective identification of candidates for deferred therapy is not standardized and many patients receive immediate therapy regardless of risk. We conducted a retrospective, multi-center cohort analysis of MCL patients with comprehensive clinical data to examine the use and safety of deferred therapy for newly diagnosed patients. Previously untreated patients ≥18 years-old with MCL diagnosed in 1993–2015 at five academic sites were included. Of 395 patients, 72 (18%) received deferred therapy (defined as receipt of first treatment >90 days following initial diagnosis). Patients receiving deferred therapy were more likely to have an ECOG performance status of 0 (67 versus 44% p =.001), have no B symptoms (83 versus 65% p =.003) and have normal LDH levels at diagnosis (87 versus 55% p <.001). In multivariable analysis, deferred therapy was not associated with a significant difference in OS (HR 0.64: 95% CI 0.22–1.84, p =.407).
AB - Prospective identification of candidates for deferred therapy is not standardized and many patients receive immediate therapy regardless of risk. We conducted a retrospective, multi-center cohort analysis of MCL patients with comprehensive clinical data to examine the use and safety of deferred therapy for newly diagnosed patients. Previously untreated patients ≥18 years-old with MCL diagnosed in 1993–2015 at five academic sites were included. Of 395 patients, 72 (18%) received deferred therapy (defined as receipt of first treatment >90 days following initial diagnosis). Patients receiving deferred therapy were more likely to have an ECOG performance status of 0 (67 versus 44% p =.001), have no B symptoms (83 versus 65% p =.003) and have normal LDH levels at diagnosis (87 versus 55% p <.001). In multivariable analysis, deferred therapy was not associated with a significant difference in OS (HR 0.64: 95% CI 0.22–1.84, p =.407).
KW - Mantle cell lymphoma
KW - deferred therapy
KW - non-Hodgkin’s lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85048791473&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048791473&partnerID=8YFLogxK
U2 - 10.1080/10428194.2018.1455973
DO - 10.1080/10428194.2018.1455973
M3 - Article
C2 - 29912594
AN - SCOPUS:85048791473
SN - 1042-8194
VL - 59
SP - 2862
EP - 2870
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 12
ER -